DadFinStart your free week
DadFin › Stocks › Healthcare › LONA

LeonaBio, Inc. (LONA) stock score

Healthcare · Biotechnology · United States

$5.75 +0.00% today

70.1
Dad Score, out of 100
good

LeonaBio, Inc. (LONA) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 70.1 out of 100 on the Dad Score, a good reading that places the business ahead of 70% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #256 of 974. Its strongest axes are valuation, risk and conviction; its weakest is quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Weak
Growth
Average
Price action
Average
Risk
Strong
Conviction
Strong
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)0.0×
Dividend yield0.00%
Return on capital-236.5%
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield0.0%
Net debt / EBITDA3.00×
Piotroski F-Score2 / 9
52-week change+11.6%
Market cap$45M
Next earnings—

What subscribers see on LONA

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.